A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer
- 31 January 2011
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 38 (1), 129-136
- https://doi.org/10.1016/j.nucmedbio.2010.06.010
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer XenograftsJournal of Nuclear Medicine, 2009
- Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer TherapyJournal of Nuclear Medicine, 2009
- Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenograftsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Molecular Imaging as a Tool for Personalized and Targeted Anticancer TherapyClinical Pharmacology & Therapeutics, 2007
- Trastuzumab and Breast CancerNew England Journal of Medicine, 2001
- Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancerSeminars in Surgical Oncology, 1998
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- ERBB2 oncogene in human breast cancer and its clinical significanceEuropean Journal Of Cancer, 1998
- Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancerHuman Pathology, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987